Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton's Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee
Publication
, Journal Article
Ganatra, S; Barac, A; Armenian, S; Cambareri, C; Denlinger, CS; Dent, SF; Hayek, S; Ky, B; Leja, M; Lucas, CH; Makwana, B; Palaskas, NL; Vo, JB
Published in: Journal of the American College of Cardiology
January 1, 2025
Duke Scholars
Published In
Journal of the American College of Cardiology
DOI
EISSN
1558-3597
ISSN
0735-1097
Publication Date
January 1, 2025
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Ganatra, S., Barac, A., Armenian, S., Cambareri, C., Denlinger, C. S., Dent, S. F., … Vo, J. B. (2025). Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton's Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2025.10.018
Ganatra, S., A. Barac, S. Armenian, C. Cambareri, C. S. Denlinger, S. F. Dent, S. Hayek, et al. “Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton's Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee.” Journal of the American College of Cardiology, January 1, 2025. https://doi.org/10.1016/j.jacc.2025.10.018.
Ganatra S, Barac A, Armenian S, Cambareri C, Denlinger CS, Dent SF, et al. Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton's Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2025 Jan 1;
Ganatra, S., et al. “Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton's Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee.” Journal of the American College of Cardiology, Jan. 2025. Scopus, doi:10.1016/j.jacc.2025.10.018.
Ganatra S, Barac A, Armenian S, Cambareri C, Denlinger CS, Dent SF, Hayek S, Ky B, Leja M, Lucas CH, Makwana B, Palaskas NL, Vo JB. Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton's Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2025 Jan 1;
Published In
Journal of the American College of Cardiology
DOI
EISSN
1558-3597
ISSN
0735-1097
Publication Date
January 1, 2025
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology